Donor Age Impairs Vasculogenic Potential of hiPSC-Derived Endothelial Progenitors via Elevated Mitochondrial Reactive Oxygen Species
This study demonstrates that donor age impairs the vasculogenic potential of hiPSC-derived endothelial progenitors by increasing mitochondrial reactive oxygen species through epigenetic and transcriptomic alterations, a deficit that can be rescued by antioxidant treatment to restore functional vascular network formation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body is a vast, intricate network of pipes, delivering oxygen and nutrients to every cell. When these vessels are damaged by disease or age, the body's ability to repair them often falters, leading to severe health crises. Scientists have long sought a way to grow new blood vessels in the laboratory, hoping to one day replace damaged ones in patients. A promising tool for this task is a type of laboratory-grown cell called a human induced pluripotent stem cell. These cells can be coaxed into becoming endothelial progenitors, which are the building blocks of blood vessels. They have the unique ability to self-assemble into tiny, hollow tubes that mimic real blood vessels, all without needing extra support from other cell types.
However, a critical gap exists in how this research is currently conducted. Most studies use cells derived from newborns or very young donors, whose biology is pristine and highly adaptable. Yet, the people who will eventually receive these therapies are typically older adults, whose cells have aged and accumulated changes over decades. It remains unclear whether cells grown from older donors can perform the same complex tasks as those from the young. If the age of the donor cell fundamentally alters its ability to build new vessels, then the promising therapies developed in the lab might fail when applied to the very patients who need them most.
Researchers at The University of Texas at Austin set out to solve this mystery by comparing cells from three newborn donors against cells from three mature donors, all over thirty years old. They carefully matched the pairs so that the only major difference was the age of the original donor, while keeping the sex and the type of tissue the cells came from identical. The team first grew these cells into endothelial progenitors and then placed them inside a soft, gel-like material designed to mimic the environment of human tissue. In this setting, the cells were free to organize themselves into a network of vessels. The results were stark and immediate. The cells from the newborn donors formed dense, highly connected webs of tubes with clear, open channels running through them. In contrast, the cells from the mature donors struggled significantly. They formed isolated clumps of cells that were poorly connected and largely failed to create the hollow channels necessary for blood flow. The mature cells simply could not build the robust vascular networks that the younger cells created with ease.
To understand why this failure occurred, the scientists looked deeper into the biology of the cells. They examined the chemical tags on the DNA that act as switches, turning genes on or off, and found that the older cells carried a different epigenetic signature. More importantly, they discovered a specific flaw in the powerhouses of the cells, known as mitochondria. In the cells from the mature donors, these powerhouses were producing excessive amounts of reactive oxygen species, a type of damaging chemical stress, while their internal energy potential was lower than in the younger cells. This buildup of internal stress appeared to be the primary driver of the dysfunction, causing the cells to lose their ability to organize into proper vessels.
The researchers then tested whether they could fix this problem by treating the mature cells with a specialized antioxidant designed to neutralize the damaging oxygen species specifically within the mitochondria. When they applied this treatment to the mature donor cells before they were turned into vessel-building progenitors, the outcome changed dramatically. The treated cells began to behave like the newborn cells. They regained their ability to form complex, interconnected networks with open channels, matching the performance of the young donor cells almost perfectly. This intervention also reversed the chemical changes in their DNA and the patterns of gene activity, effectively resetting the cells to a more youthful, functional state.
This work highlights a crucial barrier in the path toward personalized medicine. It suggests that simply taking a patient's own cells and turning them into new tissue may not be enough if those cells come from an older individual, as the age-related damage can impair their function. However, the study also offers a potential solution. By identifying and correcting the specific internal stress caused by aging, scientists may be able to restore the regenerative power of cells from older patients. This finding underscores that for future therapies to succeed in the real world, researchers must account for the age of the donor and develop strategies to overcome the biological hurdles that come with growing older.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.